Fluoxetine

Evidence Level: L3

Predicted Indications: 8

Fluoxetine

Pharmacist Assessment Report

One-Sentence Summary

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) used for depressive disorders, anxiety, obsessive-compulsive disorder and bulimia nervosa. The TxGNN model predicts it may help in schizotypal personality disorder. Support is limited: no registered clinical trials and 10 publications, only a few of which address this condition directly (one small, open-label study of 22 patients with borderline or schizotypal personality disorder).

Quick Overview

Item	Content
Original Indication	Depressive disorders, anxiety disorders, obsessive-compulsive disorder and bulimia nervosa (relations recorded in the knowledge graph; the Canadian licence records compiled for this report contain no indication text)
Predicted New Indication	Schizotypal personality disorder
TxGNN Prediction Score	0.9992
Evidence Level	L3
Canada Market Status	Marketed (marketed DINs on record: at least 19; dormant: 1)
Number of DINs	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data are not available in the data compiled for this report. Fluoxetine is known as an SSRI, and it blocks the reuptake of serotonin in the brain. Its use in mood, anxiety and obsessive-compulsive conditions is recorded in the knowledge graph. Mechanistically, it may be applicable to schizotypal personality disorder.

Schizotypal personality disorder shares features with those conditions, including affective instability, anxiety, and obsessive or impulsive symptoms. Dampening these through serotonergic modulation is the plausible link. The evidence is old and small. The most direct source is a 1991 non-blind, 12-week study of 22 patients with borderline or schizotypal personality disorder, or both. It reported reduced self-injury and lower symptom-checklist scores regardless of diagnosis. The authors concluded that controlled trials would be useful. It did not separate schizotypal patients from borderline patients.

Reviews of personality disorder pharmacotherapy state that there is no agent of choice for schizotypal personality disorder. Several drug classes may help selected patients, depending on the symptoms they present.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

No randomized controlled trials were found. The table lists the most relevant publications, with direct and review evidence first.

PMID	Year	Type	Journal	Key Findings
1853957	1991	Open-label clinical study	Am J Psychiatry	22 patients with borderline or schizotypal personality disorder took fluoxetine for 12 weeks. Self-injury and symptom scores fell significantly. The sample was mixed and there was no control group.
9448667	1998	Clinical outcome review	J Clin Psychiatry	No agent of choice exists for borderline or schizotypal personality disorder. Several drug classes help selected patients, depending on symptoms.
29955451	2016	Review	Ment Health Clin	Reviews pharmacologic treatment of cluster A personality disorders (paranoid, schizoid, schizotypal).
8227492	1993	Review	J Clin Psychopharmacol	Conceptual framework and efficacy data for medications in personality disorders.
12214786	2002	Review (indirect)	Psychol Med	Personality disorder diagnoses were assessed in depressed outpatients before and after fluoxetine treatment.
15209835	2004	Cohort (indirect)	Aust N Z J Psychiatry	Personality traits and treatment outcome in bipolar II disorder versus major depression.
9664779	1998	Case report	Psychosomatics	Transient psychosis with psychogenic polydipsia in a schizotypal patient taking fluoxetine (an adverse event).
33634761	2021	Case report	CNS Neurol Disord Drug Targets	Catatonia treated with asenapine in a patient with schizotypal personality disorder. It does not involve fluoxetine.

Canada Market Information

Fluoxetine is marketed in Canada as a single-ingredient product. The records compiled for this report show at least 20 valid licences, and the list may be partial. Dosage form and approved-indication text are not included in these records. The first five are shown.

DIN	Product Name
02216582	TEVA-FLUOXETINE
02448424	BIO-FLUOXETINE
02305461	RIVA-FLUOXETINE
02385635	AURO-FLUOXETINE
02529432	M-FLUOXETINE

Safety Considerations

Contraindication-type relations in the knowledge graph (not label text):
- Mood and neurological conditions: bipolar disorder and major affective disorder, epilepsy.
- Liver and metabolic conditions: liver disease and liver failure, cirrhosis, gallbladder disease, diabetes mellitus, hyperglycemia, diabetic ketoacidosis, hyperlipidemia and hypertriglyceridemia, obesity.
- Cardiovascular conditions: orthostatic hypotension and other hypotensive disorders, stroke and cerebrovascular disorders, myocardial infarction, coronary thrombosis.
- Blood and other conditions: neutropenia, agranulocytosis, blood coagulation disease, benign prostatic hyperplasia, female breast carcinoma.
Drug interactions: 100 interactions are recorded.
- Major: bupropion, lorcaserin, diethylpropion, dolasetron, eliglustat, palonosetron and cisapride.
- Moderate examples: acetylsalicylic acid, morphine, clarithromycin, famotidine and loperamide.
Condition-specific signal: a published case report describes transient psychosis with psychogenic polydipsia in a schizotypal patient taking fluoxetine. Psychotic-spectrum patients may need closer monitoring.

Please refer to the package insert for the official warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The model score is very high, but the supporting evidence is one small, uncontrolled, mixed-diagnosis study plus narrative reviews. There are no registered trials, and no source shows a clear benefit on core schizotypal features. The package insert safety data are also missing from the compiled data.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications, to complete safety screening.
Mechanism-of-action data and a clearer link to schizotypal features.
A controlled study (or a systematic review) specific to schizotypal personality disorder, separate from borderline personality disorder.
A safety plan for patients with psychotic-spectrum symptoms and for the major drug interactions.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.